Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735300 | 0.79 | SIRT1 (0.43) | BCHETNFRSF1A | |
| SCHEMBL5983928 | 0.79 | ALDH1A1 (0.33) | — | |
| SCHEMBL6729370 | 0.74 | — | — | |
| SCHEMBL29094798 | 0.72 | CYP19A1 (0.43) | — | |
| SCHEMBL5984765 | 0.71 | — | — | |
| SCHEMBL27551737 | 0.71 | — | — | |
| SCHEMBL5984227 | 0.70 | GABBR2 (0.34) | TNFRSF1A | |
| SCHEMBL5984261 | 0.68 | ALDH1A1 (0.30) | — | |
| SCHEMBL268060 | 0.68 | BCHE (0.41) | BCHE | |
| SCHEMBL20562244 | 0.68 | BCHE (0.41) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835754-B2 | Administering alpha-(4-hydroxy-3,5-di-tert-butylphenyl)-N-tert-octylnitrone for example | RENOVIS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | RENOVIS, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209958-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRK1, OPRD1 | BCHE 2931/4885TNFRSF1A 3227/4885 |
| US-20020165274-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | OPRL1, OPRD1, OPRK1 | BCHE 2675/4885TNFRSF1A 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.